UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 51

Sortiert nach

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Blood, 2018-04, Vol.131 (17), p.1910-1919

2018

Link zum Volltext

Verfügbarkeit prüfen

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

The Lancet (British edition), 2021-06, Vol.397 (10290), p.2151-2168

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2021-06, Vol.397 (10290), p.2169-2181

2021

Link zum Volltext

Verfügbarkeit prüfen

Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results

Journal of allergy and clinical immunology, 2022-03, Vol.149 (3), p.977-987.e14

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

The Lancet (British edition), 2019-12, Vol.394 (10214), p.2108-2117

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

JAMA dermatology (Chicago, Ill.), 2021-09, Vol.157 (9), p.1047

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension

Arthritis & rheumatology (Hoboken, N.J.), 2022-01, Vol.74 (1), p.70-80

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials

JAMA dermatology (Chicago, Ill.), 2022-04, Vol.158 (4), p.404

2022

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic and exposure-response modelling to inform upadacitinib dose selection in adolescent and adult patients with atopic dermatitis

British journal of clinical pharmacology, 2023-10, Vol.89 (10), p.3139-3151

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies

Journal of allergy and clinical immunology, 2023-01, Vol.151 (1), p.172-181

2023

Link zum Volltext

Verfügbarkeit prüfen

Fungal Infections Associated with Contaminated Methylprednisolone Injections

The New England journal of medicine, 2013-10, Vol.369 (17), p.1598-1609

2013

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials

British journal of haematology, 2018-08, Vol.182 (4), p.504-512

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis

JAAD international, 2022-03, Vol.6, p.27-36

2022

Link zum Volltext

Verfügbarkeit prüfen

Generic versus disease-specific measures of health-related quality of life in systemic lupus erythematosus

Journal of rheumatology, 2011-09, Vol.38 (9), p.1821

2011

Link zum Volltext

Verfügbarkeit prüfen

Tetramers reveal IL-17–secreting CD4⁺ T cells that are specific for U1-70 in lupus and mixed connective tissue disease

Proceedings of the National Academy of Sciences - PNAS, 2015-03, Vol.112 (10), p.3044-3049

2015

Link zum Volltext

Verfügbarkeit prüfen

Campylobacter jejuni Infections Associated With Unpasteurized Milk—Multiple States, 2012

Clinical infectious diseases, 2013-07, Vol.57 (2), p.263-266

2013

Link zum Volltext

Verfügbarkeit prüfen

Measuring outcomes in systemic lupus erythematosus clinical trials

Expert review of pharmacoeconomics & outcomes research, 2011-08, Vol.11 (4), p.455-468

2011

Link zum Volltext

Verfügbarkeit prüfen

IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice

The Journal of clinical investigation, 2008-04, Vol.118 (4), p.1417-1426

2008

Link zum Volltext

Verfügbarkeit prüfen

Natural Killer Cells From Children With Type 1 Diabetes Have Defects in NKG2D-Dependent Function and Signaling

Diabetes (New York, N.Y.), 2011-03, Vol.60 (3), p.857-866

2011

Link zum Volltext

Verfügbarkeit prüfen

Development of Th17‐Associated Interstitial Kidney Inflammation in Lupus‐Prone Mice Lacking the Gene Encoding STAT‐1

Arthritis & rheumatology (Hoboken, N.J.), 2016-05, Vol.68 (5), p.1233-1244

2016

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials

JAMA oncology, 2018-05, Vol.4 (5), p.712

2018

Link zum Volltext

Verfügbarkeit prüfen

Active and latent tuberculosis in patients with systemic lupus erythematosus living in the United States

Journal of clinical rheumatology, 2009-08, Vol.15 (5), p.226

2009

Link zum Volltext

Verfügbarkeit prüfen

528 - Rapid skin clearance and itch improvement with upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: results from a phase 3b head-to-head clinical trial (Heads Up)

British journal of dermatology (1951), 2024-02, Vol.190 (Supplement_2), p.ii30-ii31

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 51

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieInfection Control And Hospital Epidemiology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(50)
Newsletter-Artikel
(1)

Sprache

Englisch
(51)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials

Population pharmacokinetic and exposure-response modelling to inform upadacitinib dose selection in adolescent and adult patients with atopic dermatitis

Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies

Fungal Infections Associated with Contaminated Methylprednisolone Injections

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials

A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis

Generic versus disease-specific measures of health-related quality of life in systemic lupus erythematosus

Tetramers reveal IL-17–secreting CD4⁺ T cells that are specific for U1-70 in lupus and mixed connective tissue disease

Campylobacter jejuni Infections Associated With Unpasteurized Milk—Multiple States, 2012

Measuring outcomes in systemic lupus erythematosus clinical trials

IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice

Natural Killer Cells From Children With Type 1 Diabetes Have Defects in NKG2D-Dependent Function and Signaling

Development of Th17‐Associated Interstitial Kidney Inflammation in Lupus‐Prone Mice Lacking the Gene Encoding STAT‐1

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials

Active and latent tuberculosis in patients with systemic lupus erythematosus living in the United States

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

528 - Rapid skin clearance and itch improvement with upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: results from a phase 3b head-to-head clinical trial (Heads Up)

Aktive Filter

Suchergebnisse filtern